COCM
BNTX icon

Charter Oak Capital Management’s BioNTech BNTX Stock Holding History

Charter Oak Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30
Closed -$2K – 785
2020
Q4 		$2K Buy
+30
New +$2.94K ﹤0.01% 660

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Charter Oak Capital Management's BNTX Position: Q1 2021 in Review

Charter Oak Capital Management sold out of BioNTech (BNTX) in Q1 2021, closing a stake of 30 shares — an estimated $2K sold.

Charter Oak Capital Management first reported a position in BNTX in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 225 funds tracked by Wall St. Rank hold BNTX as of Q1 2021.

  • Charter Oak Capital Management reported no remaining BioNTech position as of Q1 2021 after selling out during the quarter.
  • Charter Oak Capital Management sold 30 BioNTech shares in Q1 2021, an estimated $2K.
  • Charter Oak Capital Management first reported a position in BioNTech in Q4 2020 and held it in 1 quarter.
  • Charter Oak Capital Management's BioNTech position peaked at $2K in Q4 2020.
  • 225 funds tracked by Wall St. Rank held BioNTech as of Q1 2021.

Based on Charter Oak Capital Management's 13F filing for Q1 2021, filed 17 May 2021.